Treatment Guidelines for Preoperative Radiation Therapy for Retroperitoneal Sarcoma: Preliminary Consensus of an International Expert Panel.

Published

Journal Article (Review)

PURPOSE: Evidence for external beam radiation therapy (RT) as part of treatment for retroperitoneal sarcoma (RPS) is limited. Preoperative RT is the subject of a current randomized trial, but the results will not be available for many years. In the meantime, many practitioners use preoperative RT for RPS, and although this approach is used in practice, there are no radiation treatment guidelines. An international expert panel was convened to develop consensus treatment guidelines for preoperative RT for RPS. METHODS AND MATERIALS: An expert panel of 15 academic radiation oncologists who specialize in the treatment of sarcoma was assembled. A systematic review of reports related to RT for RPS, RT for extremity sarcoma, and RT-related toxicities for organs at risk was performed. Due to the paucity of high-quality published data on the subject of RT for RPS, consensus recommendations were based largely on expert opinion derived from clinical experience and extrapolation of relevant published reports. It is intended that these clinical practice guidelines be updated as pertinent data become available. RESULTS: Treatment guidelines for preoperative RT for RPS are presented. CONCLUSIONS: An international panel of radiation oncologists who specialize in sarcoma reached consensus guidelines for preoperative RT for RPS. Many of the recommendations are based on expert opinion because of the absence of higher level evidence and, thus, are best regarded as preliminary. We emphasize that the role of preoperative RT for RPS has not been proven, and we await data from the European Organization for Research and Treatment of Cancer (EORTC) study of preoperative radiotherapy plus surgery versus surgery alone for patients with RPS. Further data are also anticipated pertaining to normal tissue dose constraints, particularly for bowel tolerance. Nonetheless, as we await these data, the guidelines herein can be used to establish treatment uniformity to aid future assessments of efficacy and toxicity.

Full Text

Duke Authors

Cited Authors

  • Baldini, EH; Wang, D; Haas, RLM; Catton, CN; Indelicato, DJ; Kirsch, DG; Roberge, D; Salerno, K; Deville, C; Guadagnolo, BA; O'Sullivan, B; Petersen, IA; Le Pechoux, C; Abrams, RA; DeLaney, TF

Published Date

  • July 1, 2015

Published In

Volume / Issue

  • 92 / 3

Start / End Page

  • 602 - 612

PubMed ID

  • 26068493

Pubmed Central ID

  • 26068493

Electronic International Standard Serial Number (EISSN)

  • 1879-355X

Digital Object Identifier (DOI)

  • 10.1016/j.ijrobp.2015.02.013

Language

  • eng

Conference Location

  • United States